Teva and alvotech announce selarsdi™ (ustekinumab-aekn) injection now available in the u.s.

Teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and alvotech (nasdaq: alvo) today announced the availability of selarsdi™ (ustekinumab-aekn) injection in the u.s., a biosimilar to stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. this is the second biosimilar now available in the u.s. market under the teva and alvotech strategic partnership. the fda has provisionally determined that selarsdi will be interchangeable with the reference biologic stelara®, following the expiration of exclusivity for the first interchangeable biosimilar, on april 30, 2025.
ALVO Ratings Summary
ALVO Quant Ranking